BCR and autoimmune disease: Upon sialoglycans engagement, CD22 negatively modulates B Cell Receptor (BCR) signaling with significant implications in maintaining tolerance to self‐antigens, mandatory to prevent autoimmune diseases and B cells related malignancies.[4, 5] The mechanism of BCR modulation involves the formation of CD22 homo‐oligomers on resting B cells by means of cis interactions.